{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:01:11Z","timestamp":1787839271366,"version":"build-2784847793"},"reference-count":15,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,9,28]],"date-time":"2012-09-28T00:00:00Z","timestamp":1348790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis & Rheumatism"],"published-print":{"date-parts":[[2012,10]]},"abstract":"Abstract<\/jats:title>\n \n Objective<\/jats:title>\n The NORAM (Nonrenal Wegener's Granulomatosis Treated Alternatively with Methotrexate [MTX]) trial demonstrated that MTX can replace cyclophosphamide (CYC) as remission\u2010inducing treatment for patients with newly diagnosed early systemic antineutrophil cytoplasmic antibody\u2013associated vasculitis. Duration of relapse\u2010free survival was longer among CYC\u2010treated patients than among MTX\u2010treated patients during short\u2010term followup. The aim of the present study was to describe the long\u2010term outcome in patients enrolled in the randomized clinical trial.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Outcome questionnaires were sent to investigators who had recruited patients for the NORAM trial. Patients treated with MTX for induction of remission (n = 49) were compared to CYC\u2010treated patients (n = 46) with respect to immunosuppressive therapy during followup, relapse\u2010free survival, mortality, and occurrence of other clinical events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The median duration of followup was 6 years (range 0.1\u201310.8 years). One patient developed end\u2010stage renal disease, and 11 died. The number of patients affected by serious infection, malignancy, or severe organ failure did not differ between treatment groups, and no difference in survival rate was observed. The duration of corticosteroid therapy was longer in the MTX group during the 18 months of the trial (\n P<\/jats:italic>\n = 0.005). During subsequent followup, patients who were in the MTX group in the NORAM trial received corticosteroids, CYC, and other immunosuppressive agents (azathioprine, MTX, and\/or mycophenolate mofetil) for longer periods than those who were in the CYC group (\n P<\/jats:italic>\n = 0.004,\n P<\/jats:italic>\n = 0.037, and\n P<\/jats:italic>\n = 0.031, respectively). The cumulative relapse\u2010free survival tended to be lower in the MTX group (\n P<\/jats:italic>\n = 0.056).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In the NORAM cohort, no difference in occurrence of major adverse events was observed between treatment groups during long\u2010term followup. However, first\u2010line treatment with MTX was associated with less effective disease control than CYC\u2010based induction therapy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/art.34547","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T12:05:50Z","timestamp":1337601950000},"page":"3472-3477","source":"Crossref","is-referenced-by-count":128,"title":["Brief Report: Long\u2010term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody\u2013associated vasculitis"],"prefix":"10.1002","volume":"64","author":[{"given":"Mikkel","family":"Faurschou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Westman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Flossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R. W.","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the European Vasculitis Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-116-6-488"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21142"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020286"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-10-200905190-00004"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780351113"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181568ec0"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00025-8"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401213"},{"key":"e_1_2_6_11_2","first-page":"1299","article-title":"Outcome and prognostic factors during the course of primary small\u2010vessel vasculitides","volume":"33","author":"Pavone L","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-9-200511010-00005"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200477"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.33361"},{"key":"e_1_2_6_15_2","first-page":"100","article-title":"Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients","volume":"35","author":"Faurschou M","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfh563"}],"container-title":["Arthritis & Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.34547","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.34547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:18:26Z","timestamp":1698751106000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.34547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,28]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1002\/art.34547"],"URL":"https:\/\/doi.org\/10.1002\/art.34547","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717948020.793453081","asserted-by":"object"}]},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,28]]}}}